Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S1W-15011 · Session 1

What representations it has made or will make to Her Majesty's Government, in the light of the higher incidence of multiple sclerosis in Sc…

Answered Asked by Mary Scanlon Con Lodged 11 Apr 2001

The question

To ask the Scottish Executive what representations it has made or will make to Her Majesty's Government, in the light of the higher incidence of multiple sclerosis in Scotland, regarding the implications for multiple sclerosis sufferers of any delay by the National Institute for Clinical Excellence in assessing drugs and technologies for the treatment of multiple sclerosis.

The answer

Answered by Susan Deacon on 1 May 2001 · 20 days after it was lodged, on time

Regular meetings take place between the Scottish Executive, the Department of Health, the National Institute for Clinical Excellence and the Health Technology Board for Scotland. Progress on the assessment of technologies for the treatment of multiple sclerosis is reviewed at these meetings.The recent decision to develop a new economic model for the assessment of beta interferon is part of a process to ensure that the advice to be made available later this year is the product of the most objective and scientifically robust methodology possible.

In the Official Report

No contribution in the Official Report cites S1W-15011 by reference.